Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.93M$2.93Mderived−3.8% vs Q4 2019 Net Income-$1.21M-$1.21MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$561,473+94.0% Operating Incomederived-$1,101,504N/M Operating Cash Flowderived$334,868N/M Free Cash Flowderived$567,439N/M Margins · derivedGross margin19.2%+9.7 pt vs Q4 2019
Operating margin-37.6%+575.0 pt vs Q4 2019
Net margin-41.2%+573.7 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 26, 2021 · 85 d after period end